论文部分内容阅读
目的:研究厄贝沙坦联合吲达帕胺对高血压合并糖尿病患者的影响。方法:选取2015年2月-2016年2月期间在我院进行治疗的100例高血压合并糖尿病患者作为本次的研究对象,按照随机数字表法的方式,将其平均分成研究组和参照组,每组各50例患者。其中研究组患者使用厄贝沙坦联合吲达帕胺进行治疗,参照组患者则仅使用吲达帕胺治疗,对比两组患者的治疗疗效。结果:研究组患者的治疗有效率明显高于参照组,并且研究组患者的SCr、BUN和24hUAER水平下降明显低于参照组,组间数据对比,差异呈现P<0.05,符合统计学意义。结论:厄贝沙坦联合吲达帕胺治疗高血压合并糖尿病的疗效比单用吲达帕胺的效果明显,值得临床广泛应用。
Objective: To investigate the effect of irbesartan and indapamide in patients with hypertension and diabetes mellitus. Methods: A total of 100 hypertensive patients with diabetes treated in our hospital from February 2015 to February 2016 were selected as the subject of this study. According to the method of random number table, they were equally divided into study group and reference group , Each group of 50 patients. Among them, the study group was treated with irbesartan and indapamide, while the reference group was treated with indapamide only, which compared the curative effect of the two groups. Results: The effective rate of treatment in study group was significantly higher than that in reference group. And the decrease of SCr, BUN and 24hUAER in study group was significantly lower than that of reference group. There was significant difference between the two groups (P <0.05), which was statistically significant. Conclusion: Irbesartan combined with indapamide in the treatment of hypertension with diabetes mellitus is more effective than indapamide. It is worthy of clinical application.